baloxavir marboxil (xofluza) Report issue

Active Ingredient History

NOW
  • Now
Baloxavir marboxil (BXM), sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B flu. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.   Wikipedia

  • SMILES: OC1=C2N(C=CC1=O)N([C@@H]3COCCN3C2=O)[C@@H]4C5=CC=CC=C5SCC6=C(F)C(F)=CC=C46
  • InChIKey: FIDLLEYNNRGVFR-CTNGQTDRSA-N
  • Mol. Mass: 483.487
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Drug Pricing (per unit)

United States

$55.3200 - $73.5449
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

baloxavir marboxil

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue